Ignite Creation Date:
2024-05-06 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05319873
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-03-18
Brief Title:
Ribociclib Tucatinib and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Sponsor:
Organization:
Jonsson Comprehensive Cancer Center